MEPSEVII is a recombinant form of human β-glucuronidase (rhGUS)
- Intended to provide exogenous GUS enzyme for uptake into cellular lysosomes via mannose-6 phosphate residues
- Helps catabolize the GAGs that accumulate in the tissues of patients with MPS VII
Glycosaminoglycans (also called GAGs) are complex molecules contained within a certain part of the cell called lysosomes.
GAGs accumulate in cells in systems throughout the body, including:
In all patients, MEPSEVII treatment resulted in reduction of urinary excretion of GAGs including chondroitin sulfate and dermatan sulfate, which was sustained with continued treatment
MEPSEVII is a recombinant human lysosomal beta glucuronidase indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Limitations of Use
The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.
BOXED WARNING AND ADDITIONAL IMPORTANT SAFETY INFORMATION
- Anaphylaxis has occurred with MEPSEVII administration, as early as the first dose, therefore appropriate medical support should be readily available when MEPSEVII is administered.
- Closely observe patients during and for 60 minutes after MEPSEVII infusion.
- Immediately discontinue the MEPSEVII infusion if the patient experiences anaphylaxis.
- Anaphylaxis to MEPSEVII was reported in 2 of 20 patients in the clinical program. The two patients with anaphylaxis to MEPSEVII during the clinical trials had one occurrence each and tolerated subsequent infusions of MEPSEVII, without recurrence.
- Consider the risks and benefits of re-administering MEPSEVII following anaphylaxis.
- Manifestations included respiratory distress, cyanosis, decreased oxygen saturation, and hypotension.
- Prior to discharge, inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care if symptoms occur.
- In a clinical trial, the most common adverse reactions occurring with MEPSEVII treatment included infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, and pruritus.
- One patient experienced a febrile convulsion during MEPSEVII treatment. The patient subsequently was re-challenged without recurrence and continued on treatment.
Use in Specific Populations
- There are no available data on MEPSEVII use in pregnant women to determine a drug-associated risk of adverse developmental outcomes.
- There are no data on the presence of MEPSEVII in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MEPSEVII and any potential adverse effects on the breastfed infant from MEPSEVII or from the underlying maternal condition.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ultragenyx at 1-888-756-8657.
Please see full Prescribing Information, including the BOXED WARNING, for a complete discussion of the risks associated with MEPSEVII.